Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...

Delve into the strategy of Viatris, a company that built its reputation around generics and is steadily moving beyond to find ...

The companies ADARx Pharmaceuticals, Electra Therapeutics, and Enveda bagged the biggest biotech funding rounds overall in ...

Three big bets in metabolic disease: the race to challenge Lilly and Novo, a pill that mimics exercise, and a gene therapy ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability ...

Known for its freezing winters, Finland is warming up to global entrepreuners and investors to boost its life science ...

Look into Spain's biotech, an ecosystem that has matured and transforms promissing science into ventures but faces challenges ...

September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals.

Two different antibody-drug conjugates (ADCs) targeting the same protein produced remarkably similar phase 3 results in relapsed small-cell lung cancer (SCLC) at WCLC 2026. Hansoh Pharma’s risvutatug ...

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...